anthrax vaccine adsorbed (AVA)

From Aaushi
Jump to navigation Jump to search

Introduction

An Al(OH)3 precipitated preparation of Bacillus anthracis protective antigen from an attenuated, non encapsulated strain of B anthracis (Sterne).

(See 'Virulence factors' under Bacillus anthracis.)

Indications

Dosage

(administration)

Notes

More general terms

Additional terms

References

  1. Jump up to: 1.0 1.1 Dixon TC et al Anthrax. N Engl J Med 1999, 341:815 PMID: https://www.ncbi.nlm.nih.gov/pubmed/10477781
  2. Jump up to: 2.0 2.1 2.2 2.3 2.4 Wright JG et al Use of Anthrax Vaccine in the United States Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 Morbidity and Mortality Weekly Report (MMWR); July 23, 2010 / 59(rr06);1-30 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20651644 <Internet> http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5906a1.htm corresponding NGC guideline withdrawn Jan 2016
  3. Lowes R Anthrax Vaccine Approved for Postexposure Protection. Medscape Oncology. Nov 24, 2015 http://www.medscape.com/viewarticle/854945?nlid=91968_3663&src=wnl_edit_newsal&uac=40275SJ&impID=899989&faf=1
    FDA News Release. November 23, 2015 FDA approves vaccine for use after known or suspected anthrax exposure. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474027.htm
  4. Jump up to: 4.0 4.1 4.2 Bower WA, Schiffer J, Atmar RL, et al. Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm Rep 0019;68(No. RR-4):1-14 https://www.cdc.gov/mmwr/volumes/68/rr/rr6804a1.htm